| Immunotherapy for advanced non–small cell lung cancer: a decade of progress MD Shields, JA Marin-Acevedo, B Pellini American Society of Clinical Oncology Educational Book 41, e105-e127, 2021 | 130 | 2021 |
| Circulating tumor DNA minimal residual disease detection of non–small-cell lung cancer treated with curative intent B Pellini, AA Chaudhuri Journal of Clinical Oncology 40 (6), 567, 2022 | 108 | 2022 |
| ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine B Pellini, N Pejovic, W Feng, N Earland, PK Harris, A Usmani, ... JCO Precision Oncology 5, 378-388, 2021 | 37 | 2021 |
| Systemic therapy in primary angiosarcoma of the spleen BP Ferreira, ET Rodler, ET Loggers, SM Pollack, RL Jones Rare tumors 4 (4), 178-180, 2012 | 27 | 2012 |
| Liquid biopsies using circulating tumor DNA in non-small cell lung cancer B Pellini, J Szymanski, RI Chin, PA Jones, AA Chaudhuri Thoracic surgery clinics 30 (2), 165-177, 2020 | 24 | 2020 |
| Commercial ctDNA assays for minimal residual disease detection of solid tumors K Chen, MD Shields, PS Chauhan, RJ Ramirez, PK Harris, MA Reimers, ... Molecular diagnosis & therapy, 1-18, 2021 | 23 | 2021 |
| The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation MT Jacobs, M Olson, BP Ferreira, R Jin, R Hachem, D Byers, C Witt, ... American Journal of Transplantation 20 (2), 589-592, 2020 | 23 | 2020 |
| Overcoming KRAS-Mutant Lung Cancer J Luo, J Ostrem, B Pellini, D Imbody, Y Stern, HS Solanki, EB Haura, ... American Society of Clinical Oncology Educational Book 41, 700-710, 2022 | 22 | 2022 |
| Emerging roles of urine-based tumor DNA analysis in bladder cancer management AA Chaudhuri, B Pellini, N Pejovic, PS Chauhan, PK Harris, JJ Szymanski, ... JCO Precision Oncology 4, 806-817, 2020 | 21 | 2020 |
| Making the rounds: exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer MD Shields, K Chen, G Dutcher, I Patel, B Pellini International Journal of Molecular Sciences 23 (16), 9006, 2022 | 18 | 2022 |
| Expression of cancer stem cell markers in basal and penta-negative breast carcinomas–a study of a series of triple-negative tumors D de Mendonça Uchôa, MS Graudenz, SM Callegari-Jacques, ... Pathology-Research and Practice 210 (7), 432-439, 2014 | 16 | 2014 |
| Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA NP Semenkovich, JJ Szymanski, N Earland, PS Chauhan, B Pellini, ... Journal for ImmunoTherapy of Cancer 11 (6), 2023 | 15 | 2023 |
| Metastatic hepatoid carcinoma of the pancreas: first description of treatment with capecitabine and temozolomide BP Ferreira, J Vasquez, A Carilli The American Journal of the Medical Sciences 353 (6), 610-612, 2017 | 14 | 2017 |
| Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data JA Marin-Acevedo, B Pellini, EMO Kimbrough, JK Hicks, A Chiappori Cancers 15 (3), 629, 2023 | 12 | 2023 |
| Immune checkpoint inhibitors and chemoradiation for limited-stage small cell lung cancer B Schlick, MD Shields, JA Marin-Acevedo, I Patel, B Pellini Current Treatment Options in Oncology 23 (8), 1104-1120, 2022 | 11 | 2022 |
| White blood cell game: a teaching method L Schneider, DS Oliveira, ACP Strapasson, BP Ferreira, CG Molina, ... International Journal of Health Promotion and Education 50 (6), 311-317, 2012 | 11 | 2012 |
| Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non–small cell lung cancer B Pellini, RW Madison, MA Childress, ST Miller, O Gjoerup, J Cheng, ... Clinical Cancer Research 29 (22), 4596-4605, 2023 | 10 | 2023 |
| A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations S Devarakonda, B Pellini, L Verghese, H Park, D Morgensztern, ... Journal of Thoracic Disease 13 (7), 4054, 2021 | 10 | 2021 |
| Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma B Pellini Ferreira, M Redman, KK Baker, R Martins, KD Eaton, LQM Chow, ... The Laryngoscope 127 (7), 1583-1588, 2017 | 9 | 2017 |
| Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF … PA Jänne, F Bigot, K Papadopoulos, L Eberst, D Sommerhalder, ... Molecular Cancer Therapeutics 22 (12_Supplement), PR014-PR014, 2023 | 7 | 2023 |
